Pulmonary Drugs Market Size by Drug Class, Application, Distribution Channel, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2029
3.5%
CAGR (2023-2029)
60.95 USD Bn.
Market Size
311
Report Pages
142
Market Tables
Overview
Pulmonary Drugs Market size is expected to reach US$ 77.55 Bn. by year 2029 at a CAGR of 3.5% during the forecast period.
Pulmonary drugs are the medications which are indicated for the treatment of several types of pulmonary disease such as asthma, pneumonia, allergic rhinitis, pulmonary hypertension, and others.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
To know about the Research Methodology :- Request Free Sample Report
The global pulmonary drug market is primarily driven by increasing incidence of chronic respiratory diseases, tobacco smoking, and government & non-government initiatives. Other factors like the increase in disposable income, rise in investments for R&D, and increasing healthcare spending are opportunities driving the global pulmonary drugs market. Also, the entrance of innovative and effective drugs in the pulmonary drugs market and substantial investments in the emerging of respiratory drug delivery systems is expected to drive the future of the market.
On the other hand, the availability of counterfeit drugs, patent expiry of drugs, and increasing manufactures of generic medicines in the pulmonary drugs market might hamper the growth.
Based on the drug classes, the combination drugs segment holds the largest market share as it is comparatively nontoxic than the other drugs and key companies face no competition from generic alternatives. Additionally, the emergence of advanced and inexpensive drug delivery systems and the advent of triple combination drugs are expected to stimulate the market segment throughout the forecast period.
Region-wise, North America has the dominant share in the global pulmonary drugs market and can be attributed to the growing number of respiratory diseases in the region. According to the Centers for Disease Control and Prevention (CDC), 2021, the number of adults aged 18 and over who currently have asthma in the U.S. are 19.10 million.
Also, the Asia-Pacific region is expected to be the fastest-growing market throughout the forecast period, thanks to the rapidly improving healthcare infrastructure and the presence of a broad base of the target population. The rise of disposable income and their growing expenditure on healthcare boost the pulmonary drug market in the Asia Pacific region.
The report covers recent development of the market for pulmonary drugs such as January 2019, the U.S. Food and Drug Administration approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older in patients with COPD.
The objective of the report is to present comprehensive analysis of global pulmonary drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding global pulmonary drugs market dynamics, structure by analyzing the market segments, and project the global pulmonary drugs market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global pulmonary drugs market make the report investor’s guide.
Pulmonary Drugs Market Scope : Inquire before buying
| Pulmonary Drugs Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 60.95 Bn. |
| Forecast Period 2023 to 2029 CAGR: | 3.5% | Market Size in 2029: | US $ 77.55 Bn. |
| Segments Covered: | by Drug Class | Inhaled Corticosteroids (ICS) Long-Acting Beta2-Agonists (LABA) Antihistamines Vasodilators Short-Acting Beta2-Agonists (SABA) Anticholinergics Combination Drugs Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.) |
|
| by Application | Asthma & COPD Allergic Rhinitis Pulmonary Arterial Hypertension Cystic Fibrosis Others |
||
| by Distribution Channel | Hospital Pharmacies Retail Pharmacies Drug Stores E-commerce |
||
Pulmonary Drugs Market, By Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Key Players are:
1. Sunovion Pharmaceuticals Inc.
2. AstraZeneca
3. Novartis AG
4. F. Hoffmann-La Roche Ltd
5. GlaxoSmithKline plc.
6. Teva Pharmaceutical Industries Ltd.
7. Merck Sharp & Dohme Corp
8. Boehringer Ingelheim International GmbH.
9. Actelion Pharmaceuticals Ltd
10.Bayer AG
11.Sanofi SA
12.Meda Pharmaceuticals
13.Circassia Pharmaceuticals Plc.
14.Mallinckrodt Pharmaceuticals Plc.
15.Cheisi Farmaceutici S.p.A
16.Zambon Company S.p.A
17.Alaxia SAS
18.MannKind Corporation
19.OMRON Corporation
20.Mylan N.V.
21.3M
22.Koninklijke Philips N.V.
23.Sunovion Pharmaceuticals, Inc.
Frequently Asked Questions:
1. Which region has the largest share in Global Pulmonary Drugs Market?
Ans: North America region holds the highest share in 2022.
2. What is the growth rate of Global Pulmonary Drugs Market?
Ans: The Global Pulmonary Drugs Market is growing at a CAGR of 3.5% during forecasting period 2023-2029.
3. What is scope of the Global Pulmonary Drugs market report?
Ans: Global Pulmonary Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Pulmonary Drugs market?
Ans: The important key players in the Global Pulmonary Drugs Market are – Sunovion Pharmaceuticals Inc., AstraZeneca, Novartis AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp, Boehringer Ingelheim International GmbH., Actelion Pharmaceuticals Ltd, Bayer AG, Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceutici S.p.A, Zambon Company S.p.A, Alaxia SAS, MannKind Corporation, OMRON Corporation, Mylan N.V., 3M, Koninklijke Philips N.V., Sunovion Pharmaceuticals, and Inc.
5. What is the study period of this market?
Ans: The Global market is studied from 2022 to 2029.
Table of Contents
Global Pulmonary Drugs Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Pulmonary Drugs Market, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Antihistamines Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Pulmonary Drugs Market Analysis and Forecast
6.1. Global Pulmonary Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Pulmonary Drugs Market Analysis and Forecast, By Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Pulmonary Drugs Market Value Share Analysis, By Drug Class
7.4. Global Pulmonary Drugs Market Size (US$ Bn) Forecast, By Drug Class
7.5. Global Pulmonary Drugs Market Analysis, By Drug Class
7.6. Global Pulmonary Drugs Market Attractiveness Analysis, By Drug Class
8. Global Pulmonary Drugs Market Analysis and Forecast, By Application
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Pulmonary Drugs Market Value Share Analysis, By Application
8.4. Global Pulmonary Drugs Market Size (US$ Bn) Forecast, By Application
8.5. Global Pulmonary Drugs Market Analysis, By Application
8.6. Global Pulmonary Drugs Market Attractiveness Analysis, By Application
9. Global Pulmonary Drugs Market Analysis and Forecast, By Distribution Channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Pulmonary Drugs Market Value Share Analysis, By Distribution Channel
9.4. Global Pulmonary Drugs Market Size (US$ Bn) Forecast, By Distribution Channel
9.5. Global Pulmonary Drugs Market Analysis, By Distribution Channel
9.6. Global Pulmonary Drugs Market Attractiveness Analysis, By Distribution Channel
10. Global Pulmonary Drugs Market Analysis, by Region
10.1. Global Pulmonary Drugs Market Value Share Analysis, by Region
10.2. Global Pulmonary Drugs Market Size (US$ Bn) Forecast, by Region
10.3. Global Pulmonary Drugs Market Attractiveness Analysis, by Region
11. North America Pulmonary Drugs Market Analysis
11.1. Key Findings
11.2. North America Pulmonary Drugs Market Overview
11.3. North America Pulmonary Drugs Market Value Share Analysis, By Drug Class
11.4. North America Pulmonary Drugs Market Forecast, By Drug Class
11.4.1. Inhaled Corticosteroids (ICS)
11.4.2. Long-Acting Beta2-Agonists (LABA)
11.4.3. Antihistamines
11.4.4. Vasodilators
11.4.5. Short-Acting Beta2-Agonists (SABA)
11.4.6. Anticholinergics
11.4.7. Combination Drugs
11.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
11.5. North America Pulmonary Drugs Market Value Share Analysis, By Application
11.6. North America Pulmonary Drugs Market Forecast, By Application
11.6.1. Asthma & COPD
11.6.2. Allergic Rhinitis
11.6.3. Pulmonary Arterial Hypertension
11.6.4. Cystic Fibrosis
11.6.5. Others
11.7. North America Pulmonary Drugs Market Value Share Analysis, By Distribution Channel
11.8. North America Pulmonary Drugs Market Forecast, By Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Drug Stores
11.8.4. E-commerce
11.9. North America Pulmonary Drugs Market Value Share Analysis, by Country
11.10. North America Pulmonary Drugs Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Pulmonary Drugs Market Analysis, by Country
11.12. U.S. Pulmonary Drugs Market Forecast, By Drug Class
11.12.1. Inhaled Corticosteroids (ICS)
11.12.2. Long-Acting Beta2-Agonists (LABA)
11.12.3. Antihistamines
11.12.4. Vasodilators
11.12.5. Short-Acting Beta2-Agonists (SABA)
11.12.6. Anticholinergics
11.12.7. Combination Drugs
11.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
11.13. U.S. Pulmonary Drugs Market Forecast, By Application
11.13.1. Asthma & COPD
11.13.2. Allergic Rhinitis
11.13.3. Pulmonary Arterial Hypertension
11.13.4. Cystic Fibrosis
11.13.5. Others
11.14. U.S. Pulmonary Drugs Market Forecast, By Distribution Channel
11.14.1. Hospital Pharmacies
11.14.2. Retail Pharmacies
11.14.3. Drug Stores
11.14.4. E-commerce
11.15. Canada Pulmonary Drugs Market Forecast, By Drug Class
11.15.1. Inhaled Corticosteroids (ICS)
11.15.2. Long-Acting Beta2-Agonists (LABA)
11.15.3. Antihistamines
11.15.4. Vasodilators
11.15.5. Short-Acting Beta2-Agonists (SABA)
11.15.6. Anticholinergics
11.15.7. Combination Drugs
11.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
11.16. Canada Pulmonary Drugs Market Forecast, By Application
11.16.1. Asthma & COPD
11.16.2. Allergic Rhinitis
11.16.3. Pulmonary Arterial Hypertension
11.16.4. Cystic Fibrosis
11.16.5. Others
11.17. Canada Pulmonary Drugs Market Forecast, By Distribution Channel
11.17.1. Hospital Pharmacies
11.17.2. Retail Pharmacies
11.17.3. Drug Stores
11.17.4. E-commerce
11.18. North America Pulmonary Drugs Market Attractiveness Analysis
11.18.1. By Drug Class
11.18.2. By Application
11.18.3. By Distribution Channel
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Development
12. Europe Pulmonary Drugs Market Analysis
12.1. Key Findings
12.2. Europe Pulmonary Drugs Market Overview
12.3. Europe Pulmonary Drugs Market Value Share Analysis, By Drug Class
12.4. Europe Pulmonary Drugs Market Forecast, By Drug Class
12.4.1. Inhaled Corticosteroids (ICS)
12.4.2. Long-Acting Beta2-Agonists (LABA)
12.4.3. Antihistamines
12.4.4. Vasodilators
12.4.5. Short-Acting Beta2-Agonists (SABA)
12.4.6. Anticholinergics
12.4.7. Combination Drugs
12.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
12.5. Europe Pulmonary Drugs Market Value Share Analysis, By Application
12.6. Europe Pulmonary Drugs Market Forecast, By Application
12.6.1. Asthma & COPD
12.6.2. Allergic Rhinitis
12.6.3. Pulmonary Arterial Hypertension
12.6.4. Cystic Fibrosis
12.6.5. Others
12.7. Europe Pulmonary Drugs Market Value Share Analysis, By Distribution Channel
12.8. Europe Pulmonary Drugs Market Forecast, By Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Drug Stores
12.8.4. E-commerce
12.9. Europe Pulmonary Drugs Market Value Share Analysis, by Country
12.10. Europe Pulmonary Drugs Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Pulmonary Drugs Market Analysis, by Country
12.12. Germany Pulmonary Drugs Market Forecast, By Drug Class
12.12.1. Inhaled Corticosteroids (ICS)
12.12.2. Long-Acting Beta2-Agonists (LABA)
12.12.3. Antihistamines
12.12.4. Vasodilators
12.12.5. Short-Acting Beta2-Agonists (SABA)
12.12.6. Anticholinergics
12.12.7. Combination Drugs
12.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
12.13. Germany Pulmonary Drugs Market Forecast, By Application
12.13.1. Asthma & COPD
12.13.2. Allergic Rhinitis
12.13.3. Pulmonary Arterial Hypertension
12.13.4. Cystic Fibrosis
12.13.5. Others
12.14. Germany Pulmonary Drugs Market Forecast, By Distribution Channel
12.14.1. Hospital Pharmacies
12.14.2. Retail Pharmacies
12.14.3. Drug Stores
12.14.4. E-commerce
12.15. U.K. Pulmonary Drugs Market Forecast, By Drug Class
12.15.1. Inhaled Corticosteroids (ICS)
12.15.2. Long-Acting Beta2-Agonists (LABA)
12.15.3. Antihistamines
12.15.4. Vasodilators
12.15.5. Short-Acting Beta2-Agonists (SABA)
12.15.6. Anticholinergics
12.15.7. Combination Drugs
12.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
12.16. U.K. Pulmonary Drugs Market Forecast, By Application
12.16.1. Asthma & COPD
12.16.2. Allergic Rhinitis
12.16.3. Pulmonary Arterial Hypertension
12.16.4. Cystic Fibrosis
12.16.5. Others
12.17. U.K. Pulmonary Drugs Market Forecast, By Distribution Channel
12.17.1. Hospital Pharmacies
12.17.2. Retail Pharmacies
12.17.3. Drug Stores
12.17.4. E-commerce
12.18. France Pulmonary Drugs Market Forecast, By Drug Class
12.18.1. Inhaled Corticosteroids (ICS)
12.18.2. Long-Acting Beta2-Agonists (LABA)
12.18.3. Antihistamines
12.18.4. Vasodilators
12.18.5. Short-Acting Beta2-Agonists (SABA)
12.18.6. Anticholinergics
12.18.7. Combination Drugs
12.18.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
12.19. France Pulmonary Drugs Market Forecast, By Application
12.19.1. Asthma & COPD
12.19.2. Allergic Rhinitis
12.19.3. Pulmonary Arterial Hypertension
12.19.4. Cystic Fibrosis
12.19.5. Others
12.20. France Pulmonary Drugs Market Forecast, By Distribution Channel
12.20.1. Hospital Pharmacies
12.20.2. Retail Pharmacies
12.20.3. Drug Stores
12.20.4. E-commerce
12.21. Italy Pulmonary Drugs Market Forecast, By Drug Class
12.21.1. Inhaled Corticosteroids (ICS)
12.21.2. Long-Acting Beta2-Agonists (LABA)
12.21.3. Antihistamines
12.21.4. Vasodilators
12.21.5. Short-Acting Beta2-Agonists (SABA)
12.21.6. Anticholinergics
12.21.7. Combination Drugs
12.21.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
12.22. Italy Pulmonary Drugs Market Forecast, By Application
12.22.1. Asthma & COPD
12.22.2. Allergic Rhinitis
12.22.3. Pulmonary Arterial Hypertension
12.22.4. Cystic Fibrosis
12.22.5. Others
12.23. Italy Pulmonary Drugs Market Forecast, By Distribution Channel
12.23.1. Hospital Pharmacies
12.23.2. Retail Pharmacies
12.23.3. Drug Stores
12.23.4. E-commerce
12.24. Spain Pulmonary Drugs Market Forecast, By Drug Class
12.24.1. Inhaled Corticosteroids (ICS)
12.24.2. Long-Acting Beta2-Agonists (LABA)
12.24.3. Antihistamines
12.24.4. Vasodilators
12.24.5. Short-Acting Beta2-Agonists (SABA)
12.24.6. Anticholinergics
12.24.7. Combination Drugs
12.24.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
12.25. Spain Pulmonary Drugs Market Forecast, By Application
12.25.1. Asthma & COPD
12.25.2. Allergic Rhinitis
12.25.3. Pulmonary Arterial Hypertension
12.25.4. Cystic Fibrosis
12.25.5. Others
12.26. Spain Pulmonary Drugs Market Forecast, By Distribution Channel
12.26.1. Hospital Pharmacies
12.26.2. Retail Pharmacies
12.26.3. Drug Stores
12.26.4. E-commerce
12.27. Rest of Europe Pulmonary Drugs Market Forecast, By Drug Class
12.27.1. Inhaled Corticosteroids (ICS)
12.27.2. Long-Acting Beta2-Agonists (LABA)
12.27.3. Antihistamines
12.27.4. Vasodilators
12.27.5. Short-Acting Beta2-Agonists (SABA)
12.27.6. Anticholinergics
12.27.7. Combination Drugs
12.27.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
12.28. Rest of Europe Pulmonary Drugs Market Forecast, By Application
12.28.1. Asthma & COPD
12.28.2. Allergic Rhinitis
12.28.3. Pulmonary Arterial Hypertension
12.28.4. Cystic Fibrosis
12.28.5. Others
12.29. Rest of Europe Pulmonary Drugs Market Forecast, By Distribution Channel
12.29.1. Hospital Pharmacies
12.29.2. Retail Pharmacies
12.29.3. Drug Stores
12.29.4. E-commerce
12.30. Europe Pulmonary Drugs Market Attractiveness Analysis
12.30.1. By Drug Class
12.30.2. By Application
12.30.3. By Distribution Channel
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Development
13. Asia Pacific Pulmonary Drugs Market Analysis
13.1. Key Findings
13.2. Asia Pacific Pulmonary Drugs Market Overview
13.3. Asia Pacific Pulmonary Drugs Market Value Share Analysis, By Drug Class
13.4. Asia Pacific Pulmonary Drugs Market Forecast, By Drug Class
13.4.1. Inhaled Corticosteroids (ICS)
13.4.2. Long-Acting Beta2-Agonists (LABA)
13.4.3. Antihistamines
13.4.4. Vasodilators
13.4.5. Short-Acting Beta2-Agonists (SABA)
13.4.6. Anticholinergics
13.4.7. Combination Drugs
13.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
13.5. Asia Pacific Pulmonary Drugs Market Value Share Analysis, By Application
13.6. Asia Pacific Pulmonary Drugs Market Forecast, By Application
13.6.1. Asthma & COPD
13.6.2. Allergic Rhinitis
13.6.3. Pulmonary Arterial Hypertension
13.6.4. Cystic Fibrosis
13.6.5. Others
13.7. Asia Pacific Pulmonary Drugs Market Value Share Analysis, By Distribution Channel
13.8. Asia Pacific Pulmonary Drugs Market Forecast, By Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Drug Stores
13.8.4. E-commerce
13.9. Asia Pacific Pulmonary Drugs Market Value Share Analysis, by Country
13.10. Asia Pacific Pulmonary Drugs Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Pulmonary Drugs Market Analysis, by Country
13.12. China Pulmonary Drugs Market Forecast, By Drug Class
13.12.1. Inhaled Corticosteroids (ICS)
13.12.2. Long-Acting Beta2-Agonists (LABA)
13.12.3. Antihistamines
13.12.4. Vasodilators
13.12.5. Short-Acting Beta2-Agonists (SABA)
13.12.6. Anticholinergics
13.12.7. Combination Drugs
13.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
13.13. China Pulmonary Drugs Market Forecast, By Application
13.13.1. Asthma & COPD
13.13.2. Allergic Rhinitis
13.13.3. Pulmonary Arterial Hypertension
13.13.4. Cystic Fibrosis
13.13.5. Others
13.14. China Pulmonary Drugs Market Forecast, By Distribution Channel
13.14.1. Hospital Pharmacies
13.14.2. Retail Pharmacies
13.14.3. Drug Stores
13.14.4. E-commerce
13.15. India Pulmonary Drugs Market Forecast, By Drug Class
13.15.1. Inhaled Corticosteroids (ICS)
13.15.2. Long-Acting Beta2-Agonists (LABA)
13.15.3. Antihistamines
13.15.4. Vasodilators
13.15.5. Short-Acting Beta2-Agonists (SABA)
13.15.6. Anticholinergics
13.15.7. Combination Drugs
13.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
13.16. India Pulmonary Drugs Market Forecast, By Application
13.16.1. Asthma & COPD
13.16.2. Allergic Rhinitis
13.16.3. Pulmonary Arterial Hypertension
13.16.4. Cystic Fibrosis
13.16.5. Others
13.17. India Pulmonary Drugs Market Forecast, By Distribution Channel
13.17.1. Hospital Pharmacies
13.17.2. Retail Pharmacies
13.17.3. Drug Stores
13.17.4. E-commerce
13.18. Japan Pulmonary Drugs Market Forecast, By Drug Class
13.18.1. Inhaled Corticosteroids (ICS)
13.18.2. Long-Acting Beta2-Agonists (LABA)
13.18.3. Antihistamines
13.18.4. Vasodilators
13.18.5. Short-Acting Beta2-Agonists (SABA)
13.18.6. Anticholinergics
13.18.7. Combination Drugs
13.18.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
13.19. Japan Pulmonary Drugs Market Forecast, By Application
13.19.1. Asthma & COPD
13.19.2. Allergic Rhinitis
13.19.3. Pulmonary Arterial Hypertension
13.19.4. Cystic Fibrosis
13.19.5. Others
13.20. Japan Pulmonary Drugs Market Forecast, By Distribution Channel
13.20.1. Hospital Pharmacies
13.20.2. Retail Pharmacies
13.20.3. Drug Stores
13.20.4. E-commerce
13.21. ASEAN Pulmonary Drugs Market Forecast, By Drug Class
13.21.1. Inhaled Corticosteroids (ICS)
13.21.2. Long-Acting Beta2-Agonists (LABA)
13.21.3. Antihistamines
13.21.4. Vasodilators
13.21.5. Short-Acting Beta2-Agonists (SABA)
13.21.6. Anticholinergics
13.21.7. Combination Drugs
13.21.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
13.22. ASEAN Pulmonary Drugs Market Forecast, By Application
13.22.1. Asthma & COPD
13.22.2. Allergic Rhinitis
13.22.3. Pulmonary Arterial Hypertension
13.22.4. Cystic Fibrosis
13.22.5. Others
13.23. ASEAN Pulmonary Drugs Market Forecast, By Distribution Channel
13.23.1. Hospital Pharmacies
13.23.2. Retail Pharmacies
13.23.3. Drug Stores
13.23.4. E-commerce
13.24. Rest of Asia Pacific Pulmonary Drugs Market Forecast, By Drug Class
13.24.1. Inhaled Corticosteroids (ICS)
13.24.2. Long-Acting Beta2-Agonists (LABA)
13.24.3. Antihistamines
13.24.4. Vasodilators
13.24.5. Short-Acting Beta2-Agonists (SABA)
13.24.6. Anticholinergics
13.24.7. Combination Drugs
13.24.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
13.25. Rest of Asia Pacific Pulmonary Drugs Market Forecast, By Application
13.25.1. Asthma & COPD
13.25.2. Allergic Rhinitis
13.25.3. Pulmonary Arterial Hypertension
13.25.4. Cystic Fibrosis
13.25.5. Others
13.26. Rest of Asia Pacific Pulmonary Drugs Market Forecast, By Distribution Channel
13.26.1. Hospital Pharmacies
13.26.2. Retail Pharmacies
13.26.3. Drug Stores
13.26.4. E-commerce
13.27. Asia Pacific Pulmonary Drugs Market Attractiveness Analysis
13.27.1. By Drug Class
13.27.2. By Application
13.27.3. By Distribution Channel
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Development
14. Middle East & Africa Pulmonary Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Pulmonary Drugs Market Overview
14.3. Middle East & Africa Pulmonary Drugs Market Value Share Analysis, By Drug Class
14.4. Middle East & Africa Pulmonary Drugs Market Forecast, By Drug Class
14.4.1. Inhaled Corticosteroids (ICS)
14.4.2. Long-Acting Beta2-Agonists (LABA)
14.4.3. Antihistamines
14.4.4. Vasodilators
14.4.5. Short-Acting Beta2-Agonists (SABA)
14.4.6. Anticholinergics
14.4.7. Combination Drugs
14.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
14.5. Middle East & Africa Pulmonary Drugs Market Value Share Analysis, By Application
14.6. Middle East & Africa Pulmonary Drugs Market Forecast, By Application
14.6.1. Asthma & COPD
14.6.2. Allergic Rhinitis
14.6.3. Pulmonary Arterial Hypertension
14.6.4. Cystic Fibrosis
14.6.5. Others
14.7. Middle East & Africa Pulmonary Drugs Market Value Share Analysis, By Distribution Channel
14.8. Middle East & Africa Pulmonary Drugs Market Forecast, By Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Drug Stores
14.8.4. E-commerce
14.9. Middle East & Africa Pulmonary Drugs Market Value Share Analysis, by Country
14.10. Middle East & Africa Pulmonary Drugs Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Pulmonary Drugs Market Analysis, by Country
14.12. GCC Pulmonary Drugs Market Forecast, By Drug Class
14.12.1. Inhaled Corticosteroids (ICS)
14.12.2. Long-Acting Beta2-Agonists (LABA)
14.12.3. Antihistamines
14.12.4. Vasodilators
14.12.5. Short-Acting Beta2-Agonists (SABA)
14.12.6. Anticholinergics
14.12.7. Combination Drugs
14.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
14.13. GCC Pulmonary Drugs Market Forecast, By Application
14.13.1. Asthma & COPD
14.13.2. Allergic Rhinitis
14.13.3. Pulmonary Arterial Hypertension
14.13.4. Cystic Fibrosis
14.13.5. Others
14.14. GCC Pulmonary Drugs Market Forecast, By Distribution Channel
14.14.1. Hospital Pharmacies
14.14.2. Retail Pharmacies
14.14.3. Drug Stores
14.14.4. E-commerce
14.15. South Africa Pulmonary Drugs Market Forecast, By Drug Class
14.15.1. Inhaled Corticosteroids (ICS)
14.15.2. Long-Acting Beta2-Agonists (LABA)
14.15.3. Antihistamines
14.15.4. Vasodilators
14.15.5. Short-Acting Beta2-Agonists (SABA)
14.15.6. Anticholinergics
14.15.7. Combination Drugs
14.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
14.16. South Africa Pulmonary Drugs Market Forecast, By Application
14.16.1. Asthma & COPD
14.16.2. Allergic Rhinitis
14.16.3. Pulmonary Arterial Hypertension
14.16.4. Cystic Fibrosis
14.16.5. Others
14.17. South Africa Pulmonary Drugs Market Forecast, By Distribution Channel
14.17.1. Hospital Pharmacies
14.17.2. Retail Pharmacies
14.17.3. Drug Stores
14.17.4. E-commerce
14.18. Rest of Middle East & Africa Pulmonary Drugs Market Forecast, By Drug Class
14.18.1. Inhaled Corticosteroids (ICS)
14.18.2. Long-Acting Beta2-Agonists (LABA)
14.18.3. Antihistamines
14.18.4. Vasodilators
14.18.5. Short-Acting Beta2-Agonists (SABA)
14.18.6. Anticholinergics
14.18.7. Combination Drugs
14.18.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
14.19. Rest of Middle East & Africa Pulmonary Drugs Market Forecast, By Application
14.19.1. Asthma & COPD
14.19.2. Allergic Rhinitis
14.19.3. Pulmonary Arterial Hypertension
14.19.4. Cystic Fibrosis
14.19.5. Others
14.20. Rest of Middle East & Africa Pulmonary Drugs Market Forecast, By Distribution Channel
14.20.1. Hospital Pharmacies
14.20.2. Retail Pharmacies
14.20.3. Drug Stores
14.20.4. E-commerce
14.21. Middle East & Africa Pulmonary Drugs Market Attractiveness Analysis
14.21.1. By Drug Class
14.21.2. By Application
14.21.3. By Distribution Channel
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Development
15. South America Pulmonary Drugs Market Analysis
15.1. Key Findings
15.2. South America Pulmonary Drugs Market Overview
15.3. South America Pulmonary Drugs Market Value Share Analysis, By Drug Class
15.4. South America Pulmonary Drugs Market Forecast, By Drug Class
15.4.1. Inhaled Corticosteroids (ICS)
15.4.2. Long-Acting Beta2-Agonists (LABA)
15.4.3. Antihistamines
15.4.4. Vasodilators
15.4.5. Short-Acting Beta2-Agonists (SABA)
15.4.6. Anticholinergics
15.4.7. Combination Drugs
15.4.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
15.5. South America Pulmonary Drugs Market Value Share Analysis, By Application
15.6. South America Pulmonary Drugs Market Forecast, By Application
15.6.1. Asthma & COPD
15.6.2. Allergic Rhinitis
15.6.3. Pulmonary Arterial Hypertension
15.6.4. Cystic Fibrosis
15.6.5. Others
15.7. South America Pulmonary Drugs Market Value Share Analysis, By Distribution Channel
15.8. South America Pulmonary Drugs Market Forecast, By Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Drug Stores
15.8.4. E-commerce
15.9. South America Pulmonary Drugs Market Value Share Analysis, by Country
15.10. South America Pulmonary Drugs Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Pulmonary Drugs Market Analysis, by Country
15.12. Brazil Pulmonary Drugs Market Forecast, By Drug Class
15.12.1. Inhaled Corticosteroids (ICS)
15.12.2. Long-Acting Beta2-Agonists (LABA)
15.12.3. Antihistamines
15.12.4. Vasodilators
15.12.5. Short-Acting Beta2-Agonists (SABA)
15.12.6. Anticholinergics
15.12.7. Combination Drugs
15.12.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
15.13. Brazil Pulmonary Drugs Market Forecast, By Application
15.13.1. Asthma & COPD
15.13.2. Allergic Rhinitis
15.13.3. Pulmonary Arterial Hypertension
15.13.4. Cystic Fibrosis
15.13.5. Others
15.14. Brazil Pulmonary Drugs Market Forecast, By Distribution Channel
15.14.1. Hospital Pharmacies
15.14.2. Retail Pharmacies
15.14.3. Drug Stores
15.14.4. E-commerce
15.15. Mexico Pulmonary Drugs Market Forecast, By Drug Class
15.15.1. Inhaled Corticosteroids (ICS)
15.15.2. Long-Acting Beta2-Agonists (LABA)
15.15.3. Antihistamines
15.15.4. Vasodilators
15.15.5. Short-Acting Beta2-Agonists (SABA)
15.15.6. Anticholinergics
15.15.7. Combination Drugs
15.15.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
15.16. Mexico Pulmonary Drugs Market Forecast, By Application
15.16.1. Asthma & COPD
15.16.2. Allergic Rhinitis
15.16.3. Pulmonary Arterial Hypertension
15.16.4. Cystic Fibrosis
15.16.5. Others
15.17. Mexico Pulmonary Drugs Market Forecast, By Distribution Channel
15.17.1. Hospital Pharmacies
15.17.2. Retail Pharmacies
15.17.3. Drug Stores
15.17.4. E-commerce
15.18. Rest of South America Pulmonary Drugs Market Forecast, By Drug Class
15.18.1. Inhaled Corticosteroids (ICS)
15.18.2. Long-Acting Beta2-Agonists (LABA)
15.18.3. Antihistamines
15.18.4. Vasodilators
15.18.5. Short-Acting Beta2-Agonists (SABA)
15.18.6. Anticholinergics
15.18.7. Combination Drugs
15.18.8. Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
15.19. Rest of South America Pulmonary Drugs Market Forecast, By Application
15.19.1. Asthma & COPD
15.19.2. Allergic Rhinitis
15.19.3. Pulmonary Arterial Hypertension
15.19.4. Cystic Fibrosis
15.19.5. Others
15.20. Rest of South America Pulmonary Drugs Market Forecast, By Distribution Channel
15.20.1. Hospital Pharmacies
15.20.2. Retail Pharmacies
15.20.3. Drug Stores
15.20.4. E-commerce
15.21. South America Pulmonary Drugs Market Attractiveness Analysis
15.21.1. By Drug Class
15.21.2. By Application
15.21.3. By Distribution Channel
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Development
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Sunovion Pharmaceuticals Inc.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Company Footprint
16.3.2. AstraZeneca
16.3.3. Novartis AG
16.3.4. F. Hoffmann-La Roche Ltd
16.3.5. GlaxoSmithKline plc.
16.3.6. Teva Pharmaceutical Industries Ltd.
16.3.7. Merck Sharp & Dohme Corp
16.3.8. Boehringer Ingelheim International GmbH.
16.3.9. Actelion Pharmaceuticals Ltd
16.3.10. Bayer AG
16.3.11. Sanofi SA
16.3.12. Meda Pharmaceuticals
16.3.13. Circassia Pharmaceuticals Plc.
16.3.14. Mallinckrodt Pharmaceuticals Plc.
16.3.15. Cheisi Farmaceutici S.p.A
16.3.16. Zambon Company S.p.A
16.3.17. Alaxia SAS
16.3.18. MannKind Corporation
16.3.19. OMRON Corporation
16.3.20. Mylan N.V.
16.3.21. 3M
16.3.22. Koninklijke Philips N.V.
16.3.23. Sunovion Pharmaceuticals, Inc.
17. Primary Key Insights